Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rangering i aksjer
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Aksjekurs
$4.48
Markedsverdi
$4.99B
Endring (1 dag)
-5.20%
Endring (1 år)
-41.89%
Land
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategori
Healthcare
EPS for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
EPS per June 2026 TTM: $0.09
Ifølge de siste økonomiske rapportene og aksjekursen til Shenzhen Salubris Pharmaceuticals Co., Ltd. er selskapets nåværende EPS (TTM) $0.09. Ved slutten av 2024 hadde selskapet en EPS på $0.07, lik EPS-en i 2023 som var $0.07.
EPS-historikk for Shenzhen Salubris Pharmaceuticals Co., Ltd. fra 2006 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $0.09 | 12.25% |
| 2025 | $0.08 | 12.03% |
| 2024 | $0.07 | 0.68% |
| 2023 | $0.07 | -12.60% |
| 2022 | $0.08 | 6.86% |
| 2021 | $0.08 | 764.84% |
| 2020 | $0.01 | -90.82% |
| 2019 | $0.10 | -50.96% |
| 2018 | $0.20 | -5.38% |
| 2017 | $0.21 | 11.48% |
| 2016 | $0.19 | 2.84% |
| 2015 | $0.19 | 15.43% |
| 2014 | $0.16 | 23.96% |
| 2013 | $0.13 | 33.13% |
| 2012 | $0.10 | 58.00% |
| 2011 | $0.06 | 20.19% |
| 2010 | $0.05 | 40.71% |
| 2009 | $0.04 | 66.36% |
| 2008 | $0.02 | 71.88% |
| 2007 | $0.01 | 91.04% |
| 2006 | $0.01 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $8.37 | 9,220.71% |
US
|
|
| $6.41 | 7,032.74% |
FR
|
|
| - | - |
JP
|
|
| $3.32 | 3,597.10% |
US
|
|
| - | - |
CH
|
